Phasefocus Livecyte quantitative, label-free live cell imaging

20:00 EDT 30 Apr 2019 | Australian Life Scientist

Time-lapse imaging is a fundamental tool for studying the behaviour of cells; however, studies of primary cells in complex co-culture environments often require a high level of illumination and fluorescent labelling, which can perturb their natural function over time. Livecyte overcomes this challenge by using a modality called ptychography, which enables quantitative label-free live cell analysis of single and multiple cell types in heterogeneous cell populations.

Ptychography is a non-destructive, non-invasive technique that uses quantitative phase information to support high-contrast, label-free time lapse imaging of living cells. It reconstructs an image from overlapping diffraction patterns using a special algorithm. The technique not only has the ability to generate high-contrast images of cells, eg, neurite elongation in neuronal cells, and to provide a measure of cell proliferation and motility, it also enables users to phenotypically fingerprint cells within a cell population, all without labelling.

The low level of illumination required by the Livecyte system provides a gentle experimental environment which mimics the behaviour of cells in ‘real life’, making it suitable for analysing more clinically and physiologically relevant primary and stem cell populations, alongside traditional cell assays. The technology lends itself to a wide variety of applications, ranging from wound healing to drug discovery and the emerging field of personalised medicine.

For more information:

Original Article: Phasefocus Livecyte quantitative, label-free live cell imaging


More From BioPortfolio on "Phasefocus Livecyte quantitative, label-free live cell imaging"

Quick Search

Relevant Topic

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...